CryoPort, Inc. Completes Pilot Shipping Program for the Mayo Clinic

Market Wire, October, 2008

CryoPort, Inc. (OTCBB: CYRX) today announced that it has recently completed an initial pilot shipping program for the Mayo Clinic.

The trial involved a CryoPort Express(TM) shipment from the major biotech hub of Boston, MA to the Mayo Clinic in Rochester, MN.

Peter Berry, CEO of CryoPort, commented, "Successfully completing this initial pilot program with such an esteemed research center such as the Mayo Clinic is just a continuation of our ongoing efforts in the clinical trial space."

The shipper arrived safely and at proper temperature. The shipper then underwent an additional test to determine how long it will hold its temperature after arrival at its final destination.

Mr. Berry continued, "We continue to refine our approach toward our target markets and are beginning to see the results of our efforts. Each successful pilot program brings us one step closer to achieving our long term goals. Having recently added DuPont Crop Protection and Quest Diagnostics to our roster of clients has helped to establish and expand our credibility in the marketplace."

To be added to the CryoPort Investor email list, please email edward@carpedminc.com with CYRX in the subject line.

About CryoPort, Inc.

CryoPort ( www.cryoport.com ) develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.

"SAFE HARBOR"

This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact: Stuart Fine Carpe DM, Inc. 908-469-1788